Friday, November 26, 2021 6:55:37 PM
Marty,
I'd certainly agree that LP doesn't care about the day to day share price, but I believe she very much cares about the long term share price and/or a partnership or buyout that achieves the maximum price for all. I don't know if she's our largest share holders, but she's certainly among the biggest shareholders, especially after her options and warrants are converted to shares.
Many here like to make comparisons with CVM, I can't imagine two more different companies. CVM's CEO will issue a PR for even the most minor of issues, while LP says nearly nothing unless SEC rules say that she must. CVM has had multiple trial failures with the same drug, they just keep finding new targets to try it on, I believe it's been many years since they made any improvement on the drug itself. NWBO has had one long running pivotal trial which has been modified while underway, because of what was learned in the trial, and they've gotten the concurrence of the regulators to make the changes.
None of us like the lower share price, if we're not looking to buy cheap shares, but if you're not planning to sell, the only real concern is what it will do long term, and that's what I believe is what LP cares about.
Gary
I'd certainly agree that LP doesn't care about the day to day share price, but I believe she very much cares about the long term share price and/or a partnership or buyout that achieves the maximum price for all. I don't know if she's our largest share holders, but she's certainly among the biggest shareholders, especially after her options and warrants are converted to shares.
Many here like to make comparisons with CVM, I can't imagine two more different companies. CVM's CEO will issue a PR for even the most minor of issues, while LP says nearly nothing unless SEC rules say that she must. CVM has had multiple trial failures with the same drug, they just keep finding new targets to try it on, I believe it's been many years since they made any improvement on the drug itself. NWBO has had one long running pivotal trial which has been modified while underway, because of what was learned in the trial, and they've gotten the concurrence of the regulators to make the changes.
None of us like the lower share price, if we're not looking to buy cheap shares, but if you're not planning to sell, the only real concern is what it will do long term, and that's what I believe is what LP cares about.
Gary
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
